TRex Bio, Inc. (NASDAQ:TRXB) Sees Significant Increase in Short Interest

TRex Bio, Inc. (NASDAQ:TRXB) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 195,608 shares. Based on an average daily volume of 183,613 shares, the short-interest ratio is presently 1.1 days.

Insider Buying and Selling at TRex Bio

In related news, major shareholder Alexandria Venture Investments acquired 178,571 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the purchase, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

TRex Bio Trading Up 1.6%

TRex Bio stock traded up $0.22 during trading hours on Friday, hitting $13.74. The stock had a trading volume of 39,179 shares, compared to its average volume of 184,708. TRex Bio has a one year low of $13.10 and a one year high of $16.56.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.